FDA advisers back Gilead's cystic fibrosis drug

12/10/2009 | Reuters

An FDA panel recommended approval of Gilead Sciences' cystic fibrosis drug aztreonam to treat lung infections caused by common Pseudomonas aeruginosa bacteria in CF patients. The advisers found the treatment safe and effective when administered in 75-milligram doses three times daily.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC